SG10201912173RA - Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate - Google Patents

Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate

Info

Publication number: SG10201912173RA
Authority: SG; Singapore
Prior art keywords: drug; therapy; administration; her2 antibody; resistant cancer
Prior art date: 2016-10-07

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Family has litigation

First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=61831486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201912173R(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-10-05Application filed by Daiichi Sankyo Co LtdfiledCriticalDaiichi Sankyo Co Ltd

2020-02-27Publication of SG10201912173RApublicationCriticalpatent/SG10201912173RA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG10201912173RA2016-10-072017-10-05Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugateSG10201912173RA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2016199341		2016-10-07
JP2017097589		2017-05-16
JP2017172814		2017-09-08

Publications (1)

Publication Number	Publication Date
SG10201912173RAtrue SG10201912173RA (en)	2020-02-27

Family

ID=61831486

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201912173RASG10201912173RA (en)	2016-10-07	2017-10-05	Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate

Country Status (11)

Country	Link
US (1)	US20190330368A1 (en)
EP (1)	EP3524267A4 (en)
JP (3)	JPWO2018066626A1 (en)
KR (2)	KR20190066026A (en)
CN (1)	CN109789211A (en)
AU (2)	AU2017341000B2 (en)
BR (1)	BR112019005247A2 (en)
CA (1)	CA3036941C (en)
SG (1)	SG10201912173RA (en)
TW (2)	TWI827534B (en)
WO (1)	WO2018066626A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN118767159A (en)*	2017-08-23	2024-10-15	第一三共株式会社	Antibody-drug conjugate preparation and lyophilization thereof
US20190194348A1 (en)*	2017-11-10	2019-06-27	Oregon Health & Science University	Treatment of therapy-resistant her-2 positive breast cancer
CN112153989A (en)	2018-05-28	2020-12-29	第一三共株式会社	Treatment of HER2-mutated cancers by administration of anti-HER2 antibody-drug conjugates
TWI865337B (en)*	2018-07-25	2024-12-01	日商第一三共股份有限公司	Effective manufacturing method of antibody-drug conjugate
TW202415410A (en)	2018-07-31	2024-04-16	日商第一三共股份有限公司	Use of antibody-drug conjugate
FI3848054T3 (en)*	2018-09-06	2025-04-07	Daiichi Sankyo Co Ltd	Antibody-drug conjugates of cyclic dinucleotide derivatives
CA3133757A1 (en)	2019-03-29	2020-10-08	Medimmune Limited	Compounds and conjugates thereof
KR20220115566A (en)	2019-11-15	2022-08-17	시아겐 인크.	Methods of treating HER2-positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate
CA3168882A1 (en)	2020-02-25	2021-09-02	Mediboston, Inc.	Camptothecin derivatives and conjugates thereof
KR20230042055A (en)	2020-07-20	2023-03-27	다이이찌 산쿄 가부시키가이샤	Combinations of anti-HER2 antibody-drug conjugates with HER dimerization inhibitors
AU2021354823A1 (en)*	2020-09-30	2023-03-30	Duality Biologics (Suzhou) Co., Ltd.	Antitumor compound, and preparation method therefor and use thereof
KR102247908B1 (en)*	2020-10-08	2021-05-06	주식회사 엠디엡투스	HER2 aptamer-anticancer drug complex and use thereof
WO2022099762A1 (en)*	2020-11-12	2022-05-19	博瑞生物医药（苏州）股份有限公司	Antibody conjugate intermediate and preparation method therefor
CA3200649A1 (en)*	2020-12-11	2022-06-16	Yuli Xie	Novel camptothecin derivative, composition containing same, and use thereof
US20220378929A1 (en)*	2021-02-25	2022-12-01	MediBoston Limted	Anti-her2 antibody-drug conjugates and uses thereof
MX2023013619A (en)*	2021-05-24	2023-11-30	Remegen Co Ltd	Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer.
US11806405B1 (en)	2021-07-19	2023-11-07	Zeno Management, Inc.	Immunoconjugates and methods
CN118955615A (en)*	2022-07-05	2024-11-15	上海药明合联生物技术有限公司	Coupling Linker

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2139598T3 (en)	1990-07-10	2000-02-16	Medical Res Council	PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JP3008226B2 (en)	1991-01-16	2000-02-14	第一製薬株式会社	Hexacyclic compounds
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
DE69229477T2 (en)	1991-09-23	1999-12-09	Cambridge Antibody Technology Ltd., Melbourn	Methods for the production of humanized antibodies
ATE408012T1 (en)	1991-12-02	2008-09-15	Medical Res Council	PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
WO1993019172A1 (en)	1992-03-24	1993-09-30	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
WO1995015388A1 (en)	1993-12-03	1995-06-08	Medical Research Council	Recombinant binding proteins and peptides
JPH08337584A (en)	1995-04-10	1996-12-24	Dai Ichi Seiyaku Co Ltd	Fused hexacyclic amino compound, pharmaceutical containing the same, and process for producing the same
TW527183B (en)	1996-06-06	2003-04-11	Daiichi Seiyaku Co	Drug complex
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
MXPA01004239A (en)	1998-10-30	2002-06-04	Daiichi Seiyaku Co	Dds compounds and method for assaying the same.
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
DE10084743T1 (en)	1999-06-25	2002-08-14	Genentech Inc	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BRPI0012196B8 (en)	1999-06-25	2021-05-25	Genentech Inc	industrialized article
WO2002031140A1 (en)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions
ES3005311T3 (en)*	2014-01-31	2025-03-14	Daiichi Sankyo Co Ltd	Anti-her2 antibody-drug conjugate

2017
- 2017-10-05USUS16/334,008patent/US20190330368A1/enactivePending
- 2017-10-05EPEP17858462.9Apatent/EP3524267A4/enactivePending
- 2017-10-05SGSG10201912173RApatent/SG10201912173RA/enunknown
- 2017-10-05CNCN201780062054.2Apatent/CN109789211A/enactivePending
- 2017-10-05BRBR112019005247Apatent/BR112019005247A2/enunknown
- 2017-10-05KRKR1020197011914Apatent/KR20190066026A/ennot_activeCeased
- 2017-10-05KRKR1020237038566Apatent/KR20230158641A/enactivePending
- 2017-10-05JPJP2018543951Apatent/JPWO2018066626A1/enactivePending
- 2017-10-05WOPCT/JP2017/036215patent/WO2018066626A1/enactiveApplication Filing
- 2017-10-05AUAU2017341000Apatent/AU2017341000B2/enactiveActive
- 2017-10-05CACA3036941Apatent/CA3036941C/enactiveActive
- 2017-10-06TWTW106134472Apatent/TWI827534B/enactive
- 2017-10-06TWTW111125911Apatent/TWI868465B/enactive
2022
- 2022-04-15JPJP2022067540Apatent/JP2022095908A/enactivePending
2024
- 2024-02-07JPJP2024016749Apatent/JP2024054226A/enactivePending
2025
- 2025-02-13AUAU2025201016Apatent/AU2025201016A1/enactivePending

Also Published As

Publication number	Publication date
CA3036941A1 (en)	2018-04-12
JPWO2018066626A1 (en)	2019-07-18
WO2018066626A1 (en)	2018-04-12
US20190330368A1 (en)	2019-10-31
AU2025201016A1 (en)	2025-03-06
KR20190066026A (en)	2019-06-12
BR112019005247A2 (en)	2019-06-04
TW201818973A (en)	2018-06-01
TW202245846A (en)	2022-12-01
EP3524267A4 (en)	2020-06-10
TWI868465B (en)	2025-01-01
AU2017341000A1 (en)	2019-04-11
KR20230158641A (en)	2023-11-20
JP2022095908A (en)	2022-06-28
CA3036941C (en)	2023-02-21
CN109789211A (en)	2019-05-21
JP2024054226A (en)	2024-04-16
AU2017341000B2 (en)	2024-11-28
TWI827534B (en)	2024-01-01
EP3524267A1 (en)	2019-08-14

Publication	Publication Date	Title
SG10201912173RA (en)	2020-02-27	Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
IL291073A (en)	2022-05-01	Anti-egfr antibody drug conjugates
IL274881A (en)	2020-07-30	Anti-egfr antibody drug conjugate formulations
CY1124033T1 (en)	2022-05-27	DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
EP3448260A4 (en)	2019-10-09	Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
IL259651A (en)	2018-08-30	Site specific her2 antibody drug conjugates
SG11202006515VA (en)	2020-08-28	Preparation process of antibody drug conjugate intermediate
IL247936A0 (en)	2016-11-30	Anti-egfr antibodies and antibody drug conjugates
CL2016000468A1 (en)	2016-12-09	Anti-dll3 conjugates (ligand3 delta type) manipulated and methods of use.
EA201890530A1 (en)	2018-09-28	CONJUGATES ANTIBODIES TO DLL3 AND MEDICINES AND METHODS OF THEIR USE
EP3271401A4 (en)	2018-11-21	Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
EP3297684A4 (en)	2018-12-19	Infusion administration of conjugated monoclonal antibodies
PT3512882T (en)	2021-06-14	Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition
IL267622A (en)	2019-08-29	Method for modifying the therapeutic effects of drugs
EP3421039A4 (en)	2019-01-02	Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
SG11202104269PA (en)	2021-05-28	Anti-her2 antibody drug conjugate pharmaceutical preparation
EP3502142A4 (en)	2020-02-12	Bispecific antibody and antibody conjugate for tumour therapy and use thereof
SG11202102290RA (en)	2021-04-29	Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
IL274277A (en)	2020-06-30	Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
IL273874A (en)	2020-05-31	Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
GB201509827D0 (en)	2015-07-22	Antibody drug conjugate for treatment of cancer
EP3441465A4 (en)	2019-12-04	Cancer treatment pharmaceutical composition using anti-mct5 antibody
EA202091925A3 (en)	2020-12-30	DOSAGE AND ADMINISTRATION OF NONFUCOSYLATED ANTI-CD40 ANTIBODIES

Movatterモバイル変換